FHIR IG Statistics: ValueSet/2.16.840.1.113883.3.1444.3.138
Package | us.nlm.vsac |
Resource Type | ValueSet |
Id | 2.16.840.1.113883.3.1444.3.138 |
FHIR Version | R4 |
Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.1444.3.138/expansion |
URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.138 |
Version | 20210306 |
Status | active |
Date | 2021-03-06T01:00:16-05:00 |
Name | GranisetronTransdermal |
Title | Granisetron Transdermal |
Realm | us |
Authority | hl7 |
Purpose | (Clinical Focus: The purpose of this value set is to represent concepts of medication Granisetron.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication Granisetron; generic; prescribable; transdermal.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.) |
Resources that use this resource
Resources that this resource uses
Narrative
No narrative content found in resource
Source
{
"resourceType": "ValueSet",
"id": "2.16.840.1.113883.3.1444.3.138",
"meta": {
"versionId": "6",
"lastUpdated": "2023-12-21T17:43:03.000-05:00",
"profile": [
"http://hl7.org/fhir/StructureDefinition/shareablevalueset",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
]
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
"valueContactDetail": {
"name": "American Society of Clinical Oncology Author"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
"valueDate": "2025-04-08"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
"valueDate": "2021-03-06"
}
],
"url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.138",
"identifier": [
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113883.3.1444.3.138"
}
],
"version": "20210306",
"name": "GranisetronTransdermal",
"title": "Granisetron Transdermal",
"status": "active",
"experimental": false,
"date": "2021-03-06T01:00:16-05:00",
"publisher": "American Society of Clinical Oncology Steward",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "US"
}
]
}
],
"purpose": "(Clinical Focus: The purpose of this value set is to represent concepts of medication Granisetron.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication Granisetron; generic; prescribable; transdermal.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)",
"compose": {
"include": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"concept": [
{
"code": "825003",
"display": "168 HR granisetron 0.129 MG/HR Transdermal System"
}
]
}
]
},
"expansion": {
"identifier": "urn:uuid:7de6af77-1dc2-490c-8865-caca9a980e66",
"timestamp": "2025-05-23T21:52:57-04:00",
"total": 1,
"contains": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "825003",
"display": "168 HR granisetron 0.129 MG/HR Transdermal System"
}
]
}
}